Stemline Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.26%68.690.0%$2146.93m
NVAXNovavax, Inc. 7.86%143.7596.5%$1221.53m
SRNESorrento Therapeutics, Inc. -5.88%12.252.8%$756.06m
GILDGilead Sciences, Inc. 0.70%68.661.0%$571.95m
AMGNAmgen, Inc. 0.45%239.931.3%$470.66m
REGNRegeneron Pharmaceuticals, Inc. 0.74%615.422.7%$387.62m
VRTXVertex Pharmaceuticals, Inc. 0.06%267.301.9%$353.36m
BIIBBiogen, Inc. 0.51%290.011.6%$351.88m
BNTXBioNTech SE -1.68%69.810.0%$347.11m
ILMNIllumina, Inc. -2.35%345.223.5%$343.49m
ATNMActinium Pharmaceuticals, Inc. -0.61%9.8513.3%$235.18m
VXRTVaxart, Inc. 1.76%9.250.0%$215.96m
EBSEmergent BioSolutions, Inc. -1.00%133.596.4%$197.42m
MCRBSeres Therapeutics, Inc. -4.34%27.343.6%$178.79m
ALXNAlexion Pharmaceuticals, Inc. 1.40%103.322.0%$165.36m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.